Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sienna Biopharma acne treatment fails two studies

Sienna Biopharmaceuticals Inc.’s lead experimental acne treatment failed to meet the main goals of two pivotal trials and that the chances of it clearing a third study appeared weaker.

Read More »

Dark hair dye and chemical relaxers linked to breast cancer

African-American and white women who regularly chemically straightened their hair or dyed it dark brown or black had an elevated risk of breast cancer, recent research suggests.

Read More »

FDA lifts hold on Concert Pharma’s hair loss study

The U.S. FDA lifted a clinical hold on a trial testing Concert Pharmaceuticals Inc.’s therapy for alopecia areata, a type of hair loss.

Read More »

FDA clinical hold on Concert’s hair loss drug

Concert Pharmaceuticals Inc. said the U.S. FDA imposed a clinical hold on a trial testing the company’s drug to treat alopecia areata, a type of hair loss.

Read More »

First Gene For Grey Hair Found, University College London Study

The first gene identified for greying hair has been discovered by an international UCL-led study, confirming greying has a genetic component and is not just environmental. Published today in Nature Communications, the study analyzed a population of over 6,000 people with varied ancestry across Latin America to identify new genes associated with hair color, greying, […]

Read More »

ImmunoGen, Roche gastric cancer drug fails study

ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. ImmunoGen entered into a royalty purchase agreement with Roche for Kadcyla this year. Kadcyla, approved in 2013 for the treatment of late-stage breast cancer, was being tested as a second-line treatment […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom